



The recent completion of the human genome sequence has raised great hopes for the discovery of new breast cancer therapies based on newly-discovered genes linked to breast cancer development and progression. Here we describe breast cancer therapies that have emerged from gene-based scientific efforts over the past 20 years and that are now approved for clinical testing or treatment.

Molecular targets for breast cancer therapy and prevention

With one million new cases in the world each year, breast cancer is the most common malignancy in women and constitutes 18% of all female cancers¹. In the US breast cancer accounts for about 30% of all cancers diagnosed². Most women succumb to breast cancer when their tumors metastasize; long-term survival is more likely if the cancer remains localized. Despite surgical removal of the primary tumor in patients with apparently localized disease, relapse at local or distant sites may occur because of the presence of micrometastases undetectable at the time of diagnosis³. The development of new cytotoxic agents and radiation therapy techniques, administered as adjuvant therapy after surgery, has led to a reduction in the risk of relapse of only 20–40%, depending on the chemotherapeutic agents used⁴.

In the past, identification of therapeutic agents with demonstrable clinical benefit was an empirical process, often using cell culture cytotoxicity assays and animal tumor models that generally do not reflect complex human cancer syndromes. These non-selective approaches, whose application reaches back to the 1950s, include alkylating agents, anthracyclines, anti-metabolites and tumor antibiotics, which kill neoplastic cells by DNA damage, interference with DNA repair mechanisms and disturbance of metabolic pathways. The earliest adjuvant chemotherapy, with single-agent alkylating and anti-metabolic drugs, was soon replaced by combination therapy, as it was demonstrated that simultaneous combination of two or more agents provided better results^{5,6}. In the 1980s, many new agents became available for clinical evaluation, including the taxanes, paclitaxel and docetaxel. Taxanes are plant alkaloids that promote tubulin assembly and induce apoptosis of tumor cells by a p53-independent G₂/M cell cycle checkpoint⁷. The essential function of estrogen in breast cancer, first recognized in the 1930s, resulted in the development of tamoxifen, an antagonist of the estrogen receptor (ER) in breast tissue and the first target-directed cancer drug. Administered as endocrine therapy, tamoxifen reduces the incidence of cancer relapse in hormone-receptor-positive tumors and can delay or prevent the development of breast cancer in women at high risk⁸.

However, frequent toxic effects, including nausea, vomiting and alopecia, which are mostly acute, completely reversible and therefore tolerable, are connected with adjuvant therapies. Others, like acute leukemia, are of greater concern but occur in only about 1% of patients⁹. In addition, the emergence of multi-drug resistance poses a considerable obstacle to the success of cancer chemotherapy and endocrine therapy. As treatment of breast cancer with chemotherapy is often empirical and is mostly based on histological tumor parameters, and in the absence of specific mechanistic understanding, it has been difficult to learn from the successes and failures of new drugs. Therefore, the prevailing new rationale is aimed at the development of target-selective 'smart' drugs on the basis of characterized mechanisms of action. Fig. 1 summarizes the latest approaches for targeting breast cancer on the molecular level.

JOHANNES BANGE, ESTHER ZWICK
& AXEL ULLRICH

ERBB2 as an essential breast cancer oncogene
The epidermal growth factor receptor (EGFR) family serves as an excellent example for therapeutic targets based on studies

of tumor formation, which is defined by aberrant cell proliferation. The EGFR was the first signal-generating protein and proto-oncogene with known normal function to be cloned molecularly^{10,11}. Its overexpression correlates inversely with ER status, is often detected in invasive ductal carcinomas and is associated with poor prognosis. Inhibition of EGFR function by either monoclonal antibodies or small-molecule tyrosine kinase inhibitors of the quinazoline family have anti-tumor effects in breast carcinoma cell lines, and many EGFR-specific compounds and monoclonal antibodies are now in clinical trials^{12,13}.

The second member of the EGFR family, *ERBB2* (known as HER-2), for human epidermal growth factor receptor 2), was cloned 1 year later¹⁴ and has emerged over the past 15 years to be one of the most important oncogenes in invasive breast cancer. Amplification of *ERBB2* occurs in 30% of early-stage breast cancers, and a significant correlation between *ERBB2* overexpression and reduced survival of breast cancer patients has been found¹⁵. Moreover, *ERBB2* is not only a prognostic factor but also a predictive marker for responses to various therapeutic agents used in breast cancer therapy. *ERBB2* overexpression correlates with a lack of response to endocrine therapy and chemotherapeutic agents (Table 1). Based on the discovery of the importance of aberrant *ERBB2* overexpression in breast cancer, the monoclonal antibody against *ERBB2*, trastuzumab, was developed. This antibody, which is the first example of a genomics-based therapeutic agent that intervenes with a molecularly characterized breast-cancer-promoting mechanism, has an excellent clinical anti-tumor profile with mild side effects and was approved by the US Food and Drug Administration in 1998 for the treatment of *ERBB2*-overexpressing breast cancer in the US. When combined with chemotherapy, trastuzumab increased the overall response rate, increased the duration of response and improved the median survival time by approximately 25% compared with chemotherapy alone^{16,17}. Moreover, preclinical experiments have shown that *ERBB2* inactivation might enhance the benefit of either radiation therapy¹⁸ or tamoxifen action against *ERBB2*-overexpressing, tamoxifen-resistant breast cancer cells¹⁹.

Other molecular targets for breast cancer therapy

Both ER- and *ERBB2*-dependent mitogenic signaling have been associated with increased activation of cyclin D1, an essential factor of G1/S phase transition of the cell cycle. Upregulation of cyclin D1 has been demonstrated in cell lines overexpressing wild-type or oncogenic *ERBB2* (ref. 20). These data and the fact that cyclin D1 is overexpressed in 40% of all breast cancers identify cyclin D1 as an important molecule in tumor formation²¹. By forming a holoenzyme complex with the cyclin-dependent kinases, cyclin D1 and other members of the cyclin family regulate the transition through the cell cycle. Cyclin-dependent kinase in-




Fig. 1 Molecular targets for breast cancer therapy and chemoprevention. mAb, monoclonal antibody; E₂, estrogen; TM, transmembrane; KI, kinase inhibitor; RTK, receptor tyrosine kinase; P, phosphotyrosine residue; RAS, rous avian sarcoma homolog; RAF, murine leukemia viral oncogene homolog; MEK, mitogen-activated protein kinase kinase (MAP2K); ERK, mitogen-activated protein kinase (MAPK); Cdk, cyclin-dependent kinase; ER, estrogen receptor.

inhibitors such as p21^{Cip1}, p21^{Waf1} and p27^{Kip1} attenuate holoenzyme function and serve as negative regulators for cell cycle progression. Strategies for the direct inhibition of the function of cyclin-dependent kinases to suppress tumor growth include small molecule inhibitors such as purine derivatives and paullones²². Two of these, flavopiridol and staurosporine, have been most extensively studied in clinical trials²³; some side effects such as nausea, vomiting and diarrhea have been noted. Treatment of ERBB2-positive breast cancer cell lines with herceptin induces growth arrest by interference with cell cycle progression²⁴. Mechanistically, trastuzumab seems to work not only by inducing immune-mediated responses, internalization and downregulation of ERBB2, but also by induction of cell cycle inhibitors such as p21^{Waf1} and p27^{Kip1}.

In addition to its strong induction of mitogenic signaling in breast cancer, ERBB2 is essential in the acquired tamoxifen resistance of some breast tumors. ERBB2 overexpression is more often found in ER-negative tumors, and there is considerable evidence that the hormone independence of breast cancer may be influenced by 'cross-talk' between steroid hormones and ERBB2 pathways. For example, stimulation of cells with heregulin-β1, a ligand that activates ERBB2 by ERBB2-ERBB3 heterodimer formation, leads to enhanced deacetylase activity, suppression of histone acetylation and ER transcriptional repression²⁵. These data also indicate histone acetylation may be a potential target mechanism for therapeutic intervention in the treatment of breast cancer. Indeed, using the histone deacetylase inhibitor trichostatin A, transcriptional activation of ERα was shown in ER-negative human breast cancer cells²⁶, which indicates the possibility of reverting resistance against anti-estrogen tumor therapy. Moreover, treatment of breast cancer cells with the new histone deacetylase inhibitor suberoylanilide hydroxamic acid induces cell cycle arrest and growth inhibition, accompanied by transcriptional acti-

vation and upregulation of the cell cycle kinase inhibitor p21^{Waf1} (refs. 27,28). The therapeutic potential of suberoylanilide hydroxamic acid is now being evaluated in phase I clinical trials. In addition, the finding that the human acetylase EP300 is mutated in some epithelial cancers and behaves like a classical tumor suppressor confirms the importance of transcriptional regulation in human cancer and indicates a new field of intervention strategies²⁹. For example, expression of the DNA-binding protein PEA3 in breast cancer cell lines represses ERBB2 promoter activity and inhibits cell growth and tumor development in ERBB2-overexpressing cancer cells³⁰. Therefore, the design of transcriptional repressors that block ERBB2 expression or other cancer-relevant genes provides yet another strategy of anti-cancer treatment.

In addition to the therapeutic strategies already known, some recent reports indicate new areas for the development of target-selective drugs for the treatment of metastatic breast cancer. For example, radioiodide therapy may represent another approach, as more than 80% of human breast cancers express a specialized form of the sodium-iodide symporter that usually mediates active iodide transport in healthy lactating mammary gland but is not expressed in normal breast epithelium³¹.

Inhibition of tumor angiogenesis

Another essential process for tumor survival that can be targeted for therapy is its dependence on vascularization, or tumor angio-

Table 1 Predictive value of ERBB2 expression in breast cancer

Endocrine therapy		
Study	<i>n</i>	Correlation
Houston <i>et al.</i> ⁵⁰	241	yes
Sjogren <i>et al.</i> ⁵¹	312	yes
Archer <i>et al.</i> ⁵²	92	no
Berns <i>et al.</i> ⁵³	259	yes
Leitzel <i>et al.</i> ⁵⁴	300	yes
Nicholson <i>et al.</i> ⁵⁵	106	no
Borg <i>et al.</i> ⁵⁶	445	yes
Wright <i>et al.</i> ⁵⁷	221	yes
Chemotherapy		
Study	<i>n</i>	Correlation
Jarvinen <i>et al.</i> ⁵⁸	55	yes
Rozan <i>et al.</i> ⁵⁹	329	no
Paik <i>et al.</i> ⁶⁰	638	no ^a
Jacquemier <i>et al.</i> ⁶¹	81	no
Allred <i>et al.</i> ⁶²	613	yes ^b
Gusterson <i>et al.</i> ⁶³	1506	yes

Data represent clinical studies of ERBB2 overexpression in drug resistance of primary breast tumors. ^aERBB2-overexpressing tumors respond better to doxorubicin; ^bcorrelation identified only in a small subgroup of patients. *n*, number of patients; no, patients show no correlation between ERBB2 expression and response to adjuvant therapy; yes, patients with high ERBB2 expression showed a decreased response adjuvant therapy.



genesis. Histological progression from hyperplasia to invasive carcinoma is associated with the development of distinct microvascular structures and a complex pattern of increased angiogenic factor expression in the tumor³². Not unexpectedly, a strong correlation has been found between expression of vascular endothelial growth factor (VEGF) and increased metastasis and poor prognosis³³. Inhibition of angiogenesis has several advantages compared with other approaches in cancer therapy. These include the fact that endothelial cells are not likely to develop resistance to intervention treatments, as they are genetically stable, normal cells³⁴. Therefore, more than 20 anti-angiogenic drugs, which prevent endothelial cell proliferation directly, block activators of angiogenesis like the VEGF and fibroblast growth factor (FGF) receptors or inhibit extracellular matrix breakdown by proteases, are now undergoing evaluation in phase I, II or III clinical trials. The strategies include small molecule inhibitors, monoclonal antibodies against VEGF or integrins, and natural or synthetic inhibitors of matrix-metalloproteases³⁵. Some of the most exciting results have been obtained with small molecule inhibitors directed against the receptor tyrosine kinase FLK-1/VEGFR-2, which is essential for angiogenesis of a great variety of tumors^{36,37}. Among these Flk-1 kinase inhibitors is SU5416, the most advanced in phase III trials for the treatment of a variety of solid tumors (www.nci.nih.gov). Other kinase inhibitors that are less specific, such as SU6668, which interferes with the signaling activity of fibroblast growth factor receptor 1 and platelet-derived growth factor receptor in addition to FLK-1/VEGFR-2, are in early clinical evaluation. These anti-angiogenic drugs prevent the formation of new blood vessels and therefore inhibit further expansion of the tumor for which additional blood supply is needed. This means that anti-angiogenic therapy can control tumor progression, but its curative potential is not yet apparent.

Breast cancer chemoprevention

Most of the nonspecific cytotoxic or even target-selective therapies that have been reviewed have in common the fact that they act on late-stage carcinoma, when processes like metastasis and invasion are already underway. However, the natural progress of cancer development provides a strong rationale for preventive approaches and leads to the consideration of pharmaceutical intervention at an early stage of carcinogenesis. This strategy of arresting progression of premalignant cells by chemoprevention has become more and more attractive. The group of eligible patients include women with a biopsy-proven diagnosis of atypical epithelial hyperplasia, lobular carcinoma *in situ* or ductal carcinoma *in situ*, or patients at high risk of developing contralateral breast cancer. Moreover, the discovery of the breast cancer susceptibility genes *BRCA1* and *BRCA2* has defined carriers of mutations in *BRCA1* and *BRCA2* as a second group of candidates for chemoprevention trials.

Because estrogens are potent promoters of proliferation in normal and hyperplastic mammary epithelial cells, the first chemoprevention trials in the 1990s used the anti-estrogen tamoxifen. In the largest study, the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial, women with an increased risk of breast cancer were treated daily with tamoxifen over 5 years; the results indicated a statistically significant reduction of 49% in the incidence of breast cancer. Although two other studies did not confirm this result, the Food and Drug Administration approved tamoxifen as a chemopreventive drug for women with high risk for metastatic breast cancer. Unfortunately, side effects dependent on age and race, like stroke,

pulmonary embolism and an increase of endometrial cancer, have been reported after long-term treatment with tamoxifen^{38,39}. A new generation of selective estrogen receptor modulators such as raloxifen now offer the possibility of chemoprevention with considerably reduced risks. Like tamoxifen, raloxifen reduces the incidence of ER-positive tumors, but has no growth-promoting effect on the uterine epithelium⁴⁰. To determine whether raloxifen has fewer side effects while being as effective as tamoxifen, a project called the Study of Tamoxifen and Raloxifen is now underway.

In addition to selective estrogen receptor modulators, other non-selective estrogen-receptor-modulator classes of agents are in development for breast cancer chemoprevention. For example, based on a preclinical experimental study that demonstrated that retinoids, derivatives of vitamin A, inhibit cancer cell proliferation and show substantial anti-tumor effects, the synthetic retinoid fenretinide is now in clinical trials⁴¹. When bound to their cellular receptors, retinoids regulate proliferation and apoptosis and interfere with multiple signaling pathways, including the AP-1-dependent pathway⁴². The AP-1 transcription factor consists of members of Fos and Jun families and is important in cell proliferation and apoptosis of cells in response to stress and DNA-damaging agents. As tamoxifen resistance in certain breast cancer cells is associated with enhanced AP-1 activity⁴³, clinical application of retinoids may be useful for the treatment of hormone-insensitive breast cancer.

Non-steroidal anti-inflammatory drugs also have potent anti-neoplastic activity and reduce the relative risk of breast cancer. The anti-inflammatory effects of non-steroidal anti-inflammatory drugs stem from the blockade of the cyclooxygenase enzymes COX-1 and COX-2, which catalyze essential steps in the production of prostaglandins. These bioactive lipid molecules are over-produced in many cancers and stimulate cell proliferation, motility and tumor-associated angiogenesis. A breast cancer study in rats has provided evidence that the new COX-2 inhibitor celecoxib has strong chemopreventive activity against mammary carcinoma⁴⁴. Treatment of mice with a non-steroidal anti-inflammatory drug (sulindac) in combination with a specific EGF receptor kinase inhibitor (EKB-569) prevented the development of intestinal neoplasia⁴⁵. As levels of COX, EGFR and ERBB2 seem to be linked in a positive feedback cycle in neoplastic proliferation, inhibition of either pathway could be a useful tool for chemoprevention⁴⁶. Therefore, and because ERBB2 receptor over-expression is found in 60% of ductal carcinoma *in situ*⁴⁷, long-term treatment with herceptin or small molecule inhibitors blocking ERBB2 signaling might also be effective to prevent tumor recurrence.

New approaches in the identification of molecular targets

In the past, target-driven drug development was based on extensive research aimed at the biological function of the gene product and its potential involvement in tumor development. After confirmation of their importance in the disease process, the target molecules were used in high-throughput compound screens or in conjunction with three-dimensional structure analysis for rational drug design. Now, with the advances in cDNA array technology, this process is enhanced with respect to the number of genes investigated and the speed of data collection. Particularly for the development of 'smart drugs' intended to target only tumor cells with minimal side effects for normal cells, gene expression profiling indicates new avenues for research. Moreover, cDNA array analysis will provide new parameters for the classification of



tumor types based on gene expression profile, which will result in a more-differentiated basis for prognosis and selection of the most effective therapeutic strategies. The power of gene expression profiling has been demonstrated in many studies. For example, breast tumors are very heterogeneous in their origin and therapeutic sensitivity, and this diversity may be due to variations in the transcriptional program. Indeed, characterization of 65 surgical specimens by cDNA array analysis demonstrated many different gene profile phenotypes among the breast tumors⁴⁸. A hierarchical clustering method, which groups genes on the basis of similarity in their expression pattern, identified among other gene clusters a group of genes co-expressed together with ERBB2 and located in the same region of chromosome 17. In diffuse large B-cell lymphoma, gene expression profiling allowed the identification of distinct disease subtypes that correlated with the patients' overall survival and response to current therapy⁴⁹. Because of the power of cDNA array analysis, the future will bring substantial changes in the pathological characterization of tumors and, consequently, a better understanding of common molecular determinants of patient subpopulations that define the response to single-agent or combination therapy.

Conclusion

With the identification and characterization of signaling mechanisms that govern cell growth, differentiation, motility and apoptosis, and the elucidation of their relevance for the development of the malignant phenotype, a new era of cancer therapy has begun. Based on advances in the molecular understanding of normal and pathologically disturbed cellular signaling networks, new target-selective drugs for therapy and prevention have been developed, and many studies are underway to investigate their clinical efficacy worldwide. In combination with individual new methods of genomic diagnosis based on single-nucleotide polymorphism pattern, microarray gene expression analysis of tumor cells and computational evaluation of the resultant data, these new therapeutic agents will establish a new paradigm of therapy for cancer in general. For breast cancer, this new scientific and clinical approach was first established with the introduction of trastuzumab in 1998, but many new and promising developments are underway. Among these, cyclooxygenase inhibitors such as celecoxib, the anti-cyclin-dependent kinases cell cycle-blocking drugs and a variety of agents that interfere with tumor angiogenesis show particularly great promise and should obtain approval from the Food and Drug Administration within the next few years.

Acknowledgments

A.U. is an inventor of patents that cover anti-HER2 antibody development (Herceptin) and anti-VEGFR 2 drugs. He has no financial interest in Genentech. He is a scientific advisor to Pharmacia Corporation on the development of anti-angiogenesis drugs SU5416 and SU6668.

- McPherson, K., Steel, C.M. & Dixon, J.M. ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. *Br. Med. J.* **321**, 624–628 (2000).
- Greenlee, R.T., Murray, T., Bolden, S. & Wingo, P.A. Cancer statistics, 2000. *CA Cancer J. Clin.* **50**, 7–33 (2000).
- Saphner, T., Tormey, D.C. & Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. *J. Clin. Oncol.* **14**, 2738–2746 (1996).
- Hortobagyi, G.N. Developments in chemotherapy of breast cancer. *Cancer* **88**, 3073–3079 (2000).
- Carter, S.K. Single and combination nonhormonal chemotherapy in breast cancer. *Cancer* **30**, 1543–1555 (1972).
- Fossati, R., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. *J. Clin. Oncol.* **16**, 3439–3460 (1998).
- Lanni, J.S., Lowe, S.W., Licitra, E.J., Liu, J.O. & Jacks, T. p53-independent apoptosis

induced by paclitaxel through an indirect mechanism. *Proc. Natl. Acad. Sci. USA* **94**, 9679–9683 (1997).

- Peto, J. & Mack, T.M. High constant incidence in twins and other relatives of women with breast cancer. *Nature Genet.* **26**, 411–414 (2000).
- Hortobagyi, G. Adjuvant therapy for breast cancer. *Annu. Rev. Med.* **51**, 377–392 (2000).
- Ullrich, A., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* **309**, 418–425 (1984).
- Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. *Oncogene* **19**, 6102–6114 (2000).
- Hong, W.K. & Ullrich A.U. The role of EGFR in solid tumors and implication for therapy. *Oncol. Biotherapeutics* **1**, 1–30 (2000).
- Cardiello, F., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. *Clin. Cancer Res.* **6**, 2053–2063 (2000).
- Coussens, L., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. *Science* **230**, 1132–1139 (1985).
- Slamon, D.J., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* **235**, 177–182 (1987).
- Baselga, J. Clinical trials of Herceptin (trastuzumab). *Eur. J. Cancer* **37**, S18–S24 (2001).
- Slamon, D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N. Engl. J. Med.* **344**, 783–792 (2001).
- Pietras, R.J., et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. *Cancer Res.* **59**, 1347–1355 (1999).
- Kurokawa, H., et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. *Cancer Res.* **60**, 5887–5894 (2000).
- Lee, R.J., et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. *Mol. Cell Biol.* **20**, 672–683 (2000).
- Pestell, R.G., et al. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. *Endocrine Rev.* **20**, 501–534 (1999).
- Sausville, E.A., Johnson, J., Alley, M., Zaharevitz, D. & Senderowicz, A.M. Inhibition of CDKs as a therapeutic modality. *Ann. NY Acad. Sci.* **910**, 207–221 (2000).
- Senderowicz, A.M. & Sausville, E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. *J. Natl. Cancer Inst.* **92**, 376–387 (2000).
- Sliwkowski, M.X., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). *Semin. Oncol.* **26**, 60–70 (1999).
- Mazumdar, A., et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. *Nature Cell Biol.* **3**, 30–37 (2001).
- Yang, X., et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. *Cancer Res.* **60**, 6890–6894 (2000).
- Richon, V.M., Sandhoff, T.W., Rifkind, R.A. & Marks, P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. *Proc. Natl. Acad. Sci. USA* **97**, 10014–10019 (2000).
- Huang, L. & Pardee, A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. *Mol. Med.* **6**, 849–866 (2000).
- Gayther, S.A., et al. Mutations truncating the EP300 acetylase in human cancers. Mutations truncating the EP300 acetylase in human cancers. *Nature Genet.* **24**, 300–303 (2000).
- Xing, X., et al. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. *Nature Med.* **6**, 189–195 (2000).
- Tazebay, U.H., et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. *Nature Med.* **6**, 871–878 (2000).
- Heffelfinger, S.C., Miller, M.A., Yassin, R. & Gear, R. Angiogenic growth factors in preinvasive breast disease. *Clin. Cancer Res.* **5**, 2867–2876 (1999).
- Saariisto, A., Karpanen, T. & Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. *Oncogene* **19**, 6122–6129 (2000).
- Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. *Nature* **390**, 404–407 (1997).
- Kerbel, R.S. Tumor angiogenesis: past, present and the near future. *Carcinogenesis* **21**, 505–515 (2000).
- Millauer, B., Shawver, L.K., Plate, K.H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited *in vivo* by a dominant-negative Flk-1 mutant. *Nature* **367**, 576–579 (1994).
- Fong, T.A. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. *Cancer Res.* **59**, 99–106 (1999).
- Fisher, B., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J. Natl. Cancer Inst.* **90**, 1371–1388 (1998).
- Gail, M.H., et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J. Natl. Cancer Inst.* **91**, 1829–1846 (1999).
- Rosenbaum Smith, S.M. & Osborne, M.P. Breast cancer chemoprevention. *Am. J. Surg.* **180**, 249–251 (2000).
- Torrisi, R. & Decensi, A. Fenretinide and cancer prevention. *Curr. Oncol. Rep.* **2**, 263–270 (2000).
- Yang, L.M., Tin-U C., Wu K. & Brown, P. Role of retinoid receptor in the prevention and treatment of breast cancer. *J. Mammary Gland Biol. Neoplasia* **4**, 377–388 (1999).
- Schiff, R., et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors *in vivo*. *J. Natl. Cancer Inst.* **92**, 1926–1934 (2000).



44. Harris, R.E., Alshafie, G.A., Abou-Issa, H. & Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. *Cancer Res.* **60**, 2101–2113 (2000).
45. Torrance, C.J. *et al.* Combinatorial chemoprevention of intestinal neoplasia using an NSAID and an EGFR-kinase inhibitor. *Nature Med.* **6**, 1024–1028 (2000).
46. Vadlamuri, R. *et al.* Regulation of cyclooxygenase-2 pathway by HER2 receptor. *Oncogene* **18**, 305–314 (1999).
47. Hynes, N.E. & Stern, D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim. Biophys. Acta* **119**, 165–184 (1994).
48. Perou, C.M. *et al.* Molecular portraits of human breast tumours. *Nature* **406**, 747–752 (2000).
49. Alizadeh, A.A. *et al.* Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* **403**, 503–511 (2000).
50. Houston, S.J. *et al.* Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. *Br. J. Cancer.* **79**, 1220–1226 (1999).
51. Sjogren, S., Ingnas, M., Lindgren, A., Holmberg, L. & Bergh, J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. *J. Clin. Oncol.* **16**, 462–469 (1998).
52. Archer, S.G. *et al.* Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. *Br. J. Cancer* **72**, 1259–1266 (1995).
53. Berns, E.M. *et al.* Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. *Gene* **159**, 11–18 (1995).
54. Leitzel, K. *et al.* Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. *J. Clin. Oncol.* **13**, 1129–1135 (1995).
55. Nicholson, R.I. *et al.* Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. *Breast Cancer Res. Treat.* **29**, 117–125 (1994).
56. Borg, A. *et al.* ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. *Cancer Lett.* **81**, 137–144 (1994).
57. Wright, C. *et al.* Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. *Br. J. Cancer* **65**, 118–121 (1992).
58. Jarvinen, T.A., Holli, K., Kuukasjarvi, T. & Isola, J.J. Predictive value of topoisomerase II α and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. *Br. J. Cancer* **77**, 2267–2273 (1998).
59. Rozan, S. *et al.* No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. *Int. J. Cancer* **79**, 27–33 (1998).
60. Paik, S. *et al.*, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. *J. Natl. Cancer Inst.* **90**, 1361–1370 (1998).
61. Jacquemier, J. *et al.* Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. *Anticancer Res.* **14**, 2773–2778 (1994).
62. Allred, D.C. *et al.* Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. *Hum. Pathol.* **23**, 974–979 (1992).
63. Gusterson, B.A. *et al.* Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. *J. Clin. Oncol* **10**, 1049–1056 (1992).

Max-Planck-Institut of Biochemistry,
Department of Molecular Biology
Martinsried, Germany
Email: ullrich@biochem.mpg.de

Breast cancer results from genetic and environmental factors leading to the accumulation of mutations in essential genes. Genetic predisposition may have a strong, almost singular effect, as with *BRCA1* and *BRCA2*, or may represent the cumulative effects of multiple low-penetrance susceptibility alleles. Here we review high- and low-penetrance breast-cancer-susceptibility alleles and discuss ongoing efforts to identify additional susceptibility genes. Ultimately these discoveries will lead to individualized breast cancer risk assessment and a reduction in breast cancer incidence.

Breast cancer genetics: What we know and what we need

Although the last decade has seen many important advances in understanding genetic susceptibility to breast cancer, there remains much to learn. Unanswered questions include the number and nature of genetic variants that predispose women to breast cancer, the interplay between those variants and environmental factors, and the optimal use of that information to reduce both the personal and social costs of breast cancer. Germline mutations in *BRCA1* and *BRCA2* and a few other rare variants account for only 15–20% of breast cancer that clusters in families and less than 5% of breast cancer overall. So what are we looking for, how can we find it and how will we best use the information, once available?

The most widely accepted model of breast cancer susceptibility is that it is due to a small number of highly penetrant mutations (such as in *BRCA1* and *BRCA2*) and much larger number of low-penetrance variants (Fig. 1). Interaction between these genetic variants and environmental exposures is also important. Current efforts are aimed at identifying and characterizing these variables, but the complexities of these studies are considerable. Here we review what is known about genetic variants that predispose to breast cancer and consider ongoing efforts to identify additional high- and low-penetrance susceptibility genes.

High-penetrance mutations in known susceptibility genes

Germline mutations in *BRCA1* have been identified in 15–20% of women with a family history of breast cancer and 60–80% of women with a family history of both breast and ovarian cancer^{1,2}. Female mutation carriers have a lifetime breast cancer risk of 60–80% (refs. 3,4), although penetrance estimates as low as 36%

KATHERINE N. NATHANSON¹,
RICHARD WOOSTER² &
BARBARA L. WEBER¹

have been reported in a series of Jewish breast cancer cases selected without regard to family history⁵ (Fig. 1). The median age of diagnosis in mutation carriers is 42 years, more than 20 years earlier than the median

for unselected women in the US and Western Europe⁶. Lifetime ovarian cancer risks are estimated at 20–40%, but, unlike breast cancer, age-specific penetrance is not heavily skewed toward early onset disease^{7,8}. Increased risk⁵ for prostate and colon cancer have also been reported, with relative risks of 4.1 and 3.3, respectively⁹, and *BRCA1* mutations are found in excess in women with multiple primary cancers of any type who have both a personal and family history of breast cancer¹⁰.

BRCA1 is a large gene, with 22 exons encoding a 220-kilodalton nuclear protein with a zinc-binding RING domain at the amino terminus, and a conserved acidic carboxyl terminus¹¹ that functions in transcriptional co-activation¹². The main downstream targets identified so far are p53-responsive genes, including *p21* and *BclX*¹³. *BRCA1* binds to *BRCA2*, p53, RAD51 and many other proteins involved in cell cycling and DNA-damage response^{14,15} (Fig. 2a). The involvement of *BRCA1* in response to DNA damage is supported by extensive data, including evidence that *BRCA1* is phosphorylated by the ataxia telangiectasia mutated (ATM) and checkpoint kinase 2 (CHK2) proteins in response to DNA damage^{16,17}, that cells without functional *BRCA1* do not arrest in G2 after DNA damage and are deficient in transcription-coupled repair^{18,19}, and that *BRCA1* is part of the RAD50–MRE11–p95 complex, an essential component of recombination-mediated repair of DNA double-stranded breaks²⁰. Thus, specific involvement of *BRCA1* in DNA-damage response pathways is well-documented, but the specificity of cancer risk,